Surrozen, Inc. Common - SRZN STOCK NEWS

Surrozen, Inc. (Nasdaq: SRZN) presented preclinical data at the United European Gastroenterology Week that supports its drug candidates SZN-1326 and SZN-043 for treating ulcerative colitis and severe liver diseases, respectively. SZN-043 showed rapid hepatocyte proliferation and safety in non-clinical studies, while SZN-1326 improved epithelial healing and reduced collagen deposition. Both candidates exhibited no adverse effects in toxicology studies. The Phase 1 clinical trials for both candidates are ongoing, initiated in May and June 2022.

Surrozen has announced a significant collaboration with Boehringer Ingelheim to develop SZN-413, a bi-specific antibody aimed at treating retinal diseases. This agreement marks Surrozen's first strategic partnership and includes an upfront payment of $12.5 million, plus potential milestone payments of up to $586.5 million. SZN-413 utilizes Surrozen's SWAP™ technology to target Fzd4-mediated Wnt signaling, promoting retinal vessel regrowth and reducing vascular leakage. Boehringer will take on research and commercialization responsibilities following an initial joint research period.

Surrozen (Nasdaq: SRZN) announced promising results from recent studies published in Translational Vision Science and Technology. The research highlighted SZN-413, a bi-specific antibody targeting FZD4 and LRP5, as a potential novel treatment for diabetic retinopathy, a major cause of vision loss. SZN-413 was shown to effectively reduce retinal vascular leakage by approximately 80% and significantly diminished areas of pathologic neovascularization. This mechanism may address both retinal non-perfusion and leakage, indicating a potential breakthrough for retinal vascular diseases.

Surrozen, Inc. (SRZN) reported Q2 2022 financial results and provided a corporate update, marking its transition to a clinical stage company. The company has initiated Phase 1 trials for lead candidates SZN-1326, targeting moderate to severe ulcerative colitis, and SZN-043, aimed at severe alcoholic hepatitis. Both candidates have shown promising preclinical results without adverse effects. Additionally, preclinical data on SZN-413 for diabetic retinopathy was presented. The company emphasized ongoing advancements in its Wnt modulation therapies for tissue repair.

Surrozen, Inc. (Nasdaq: SRZN) has initiated a two-part Phase 1 clinical trial for SZN-043, a novel bispecific protein targeting ASGR1, aimed at treating severe alcoholic hepatitis. The trial's first part involves administering single doses to healthy volunteers, with doses ranging from 3 mg to 30 mg. The second part will assess multiple doses in patients with liver cirrhosis. The primary endpoint focuses on safety and tolerability. Preclinical studies indicate SZN-043 may enhance liver function and reduce fibrosis without adverse effects.

Surrozen, Inc. (NASDAQ: SRZN) announced significant advancements in its lead therapeutic programs at Digestive Disease Week 2022. The company's clinical study of SZN-1326 is currently underway, targeting moderate to severe ulcerative colitis, while the SZN-043 study is expected to commence in Q3 2022 for severe alcoholic hepatitis. Presentations highlighted SZN-1326's mechanism in promoting colonic mucosal healing and SZN-043's role in enhancing hepatocyte proliferation. Both candidates showed promising results in preclinical models, demonstrating therapeutic potential without adverse effects.

Surrozen (Nasdaq: SRZN) announced the dosing of the first subject in its three-part Phase 1 clinical trial for SZN-1326, aimed at treating moderate to severe ulcerative colitis. This milestone was achieved a quarter earlier than expected. The trial includes safety and pharmacokinetics evaluations with doses ranging from 25 mg to 1500 mg. SZN-1326, a bi-specific antibody targeting the Wnt pathway, demonstrated strong preclinical results, suggesting potential for tissue repair and anti-inflammatory effects without adverse effects observed in animal studies.

Surrozen (Nasdaq: SRZN) published results indicating that its proprietary Wnt mimetic antibody, SZN-1326, demonstrated significant potential for treating inflammatory bowel disease (IBD). The study, published in Cellular and Molecular Gastroenterology and Hepatology, utilized a mouse model and showed that SZN-1326 effectively repaired injured colon epithelium while sparing healthy tissue. With no current therapies targeting epithelial repair, Surrozen is set to initiate Phase 1 clinical trials for SZN-1326 in Q3 2022, addressing a notable medical need in ulcerative colitis management.

Surrozen, Inc. (Nasdaq: SRZN) announced financial results for Q1 2022 and provided an update on its clinical pipeline. The company is set to initiate Phase 1 clinical trials for its lead product candidates, SZN-1326 targeting moderate to severe ulcerative colitis and SZN-043 for severe alcoholic hepatitis, in Q3 2022. Both candidates demonstrated substantial efficacy in preclinical trials without adverse effects. Surrozen is also advancing SZN-413 for retinal vascular diseases, with promising preclinical data supporting its potential. The firm remains focused on transitioning to a clinical-stage organization.